Nobel Prize winners support BioMed Central and the new Faculty of 1000 literature evaluation service

October 09, 2001

Paul Nurse, a vocal supporter of BioMed Central, and Tim Hunt, a contributor to the "Faculty of 1000", have been awarded the Nobel Prize for physiology or medicine for their work on regulators of the cell cycle along with the eminent American scientist Leland Hartwell (

The cell cycle is a carefully regulated process involving the growth of a cell and the duplication of its genetic information for exact distribution into two daughter cells. When this process goes wrong it can result in uncontrolled cell division and the development of cancer. Nurse and Hunt have both made important discoveries relating to molecules involved in regulating the cell cycle which may be crucial to the development of future cancer treatments.

Paul Nurse, a founding member of the BioMed Central's Editorial Directorate, recently commented that:

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime" BioMed Central's publishing model is based on providing free access to research articles and is now receiving much attention in the scientific community. High profile endorsements of BioMed Central have helped contribute to its phenomenal growth, demonstrated by the launch of 57 new journals covering all research areas in biology and medicine in the last eighteen months.

Tim Hunt is supporting another BioMed Central venture called Faculty of 1000 ( due to be launched in January 2002. As one of the section heads for cell growth and division in the cell biology faculty, Tim Hunt will be contributing research evaluations to this exciting new literature awareness tool.
For further information on BioMed Central and Faculty of 1000 visit: and To read more about the cell cycle visit:

BioMed Central

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to